戻る
Newron Pharmaceuticals S.p.A. (NWPHF)価格
NWPHF 株価推移チャート
NWPHF 収入
Newron Pharmaceuticals S.p.A.
$12
5.26%
$0.59
本日現在の状況：Jan 20, 15:09:03 GMT-5
最新の利益結果: Q2 '25
報告済み: 2025-09-16
歴史的収益
四半期
年次
EPS
収入
Earnings FAQ
NWPHFの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
Newron Pharmaceuticals S.p.A. NWPHFの前四半期の収益はどうでしたか？
Newron Pharmaceuticals S.p.A.の収益見積もりはいくらですか？
Newron Pharmaceuticals S.p.A.の収益品質スコアはどれくらいですか？
Newron Pharmaceuticals S.p.A.はいつ収益を報告しますか？
Newron Pharmaceuticals S.p.A.の予想収益はいくらですか？
Newron Pharmaceuticals S.p.A.は収益予想を上回りましたか？
主要データ
前終値
$11.4
始値
$12
当日レンジ
$12 - $12
52週レンジ
$5.22 - $12
取引高
100
平均取引高
755
1株当たり利益(TTM)
--
配当利回り
--
時価総額
$239.5M
NEWRON PHARMACEUTICALS S.P.A.とは何ですか？
Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano and currently employs 22 full-time employees. The company went IPO on 2006-12-12. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.